BibTex format
@article{Radhakrishnan:2022:10.1111/apt.16656,
author = {Radhakrishnan, ST and Alexander, JL and Mullish, BH and Gallagher, KI and Powell, N and Hicks, LC and Hart, AL and Li, JV and Marchesi, JR and Williams, HRT},
doi = {10.1111/apt.16656},
journal = {Alimentary Pharmacology & Therapeutics},
pages = {26--48},
title = {Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease},
url = {http://dx.doi.org/10.1111/apt.16656},
volume = {55},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - <jats:title>Summary</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The gut microbiota has been implicated in the pathogenesis of inflammatory bowel disease (IBD), with <jats:italic>Faecalibacterium prausnitizii</jats:italic> associated with protection, and certain genera (including <jats:italic>Shigella</jats:italic> and <jats:italic>Escherichia</jats:italic>) associated with adverse features. The variability of patient response to medical therapies in IBD is incompletely understood. Given the recognised contribution of the microbiota to treatment efficacy in other conditions, there may be interplay between the gut microbiota, IBD medical therapy and IBD phenotype.</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>To evaluate the bidirectional relationship between IBD medical therapies and the gut microbiota.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a systematic search of MEDLINE and EMBASE. All original studies analysing interactions between the gut microbiota and established IBD medical therapies were included.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We screened 1296 records; 19 studies were eligible. There was heterogeneity in terms of sample analysis, treatment protocols, and outcome reporting. Increased baseline αdiversity was observed in responders versus nonresponders treated with exclusive enteral nutrition (EEN), infliximab, ustekinumab or vedolizumab. Higher baseline <jats:italic>Faecalibacterium</jats:italic> predicted response to infliximab and ustekinumab. A posttreatment increase in <jats:italic>Faecalibacterium prausnitzii</jats:italic> was noted in responders to aminosalicylates, antiTNF medications and ustekinumab; conversely, this speci
AU - Radhakrishnan,ST
AU - Alexander,JL
AU - Mullish,BH
AU - Gallagher,KI
AU - Powell,N
AU - Hicks,LC
AU - Hart,AL
AU - Li,JV
AU - Marchesi,JR
AU - Williams,HRT
DO - 10.1111/apt.16656
EP - 48
PY - 2022///
SN - 0269-2813
SP - 26
TI - Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease
T2 - Alimentary Pharmacology & Therapeutics
UR - http://dx.doi.org/10.1111/apt.16656
UR - http://hdl.handle.net/10044/1/92614
VL - 55
ER -